WuXi Biologics released its 2022 Environmental, Social and Governance Report, which provides a transparent and all-encompassing update on the company's efforts to advance a healthy and sustainable society.
"2022 was another record year for WuXi Biologics, with strong business momentum and sustainable high growth," said Dr. Chris Chen, WuXi Biologics CEO and ESG Committee Chairman. "We have been dedicated to infusing our core values into business development and making more positive social and environmental impacts. Over the past year, ESG concepts were deployed even deeper into our daily operations. We established multiple ESG Task Forces, advanced cross-functional collaborations on the prioritized ESG material issues, and stimulated efficient and effective improvements in our sustainability performance.
In this year's ESG Report, the Company provides transparency regarding its ESG strategy and outlines the remarkable progress on major initiatives that impact its people, global partners, communities and the environment.
Guided by its ESG strategy, WuXi Biologics aims to implement best governance practices to promote a culture of integrity and strong business ethics. In 2022, all employees participated in ethical standards and anti-corruption training. With oversight from the Board and its executive team, the Company has established comprehensive plans to address potential business risks and help ensure that the highest standards of risk-management are consistently met in its daily operations.
While continually improving its own ESG performance, WuXi Biologics also ensures that its suppliers meet the same business ethics and sustainability standards. Supplier sustainability risk assessments were implemented to identify potential risks and remediation actions were provided to help suppliers improve their sustainability management.
